Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers

European Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2008, Pages 503-509

  Niioka, Takenori ^a   Miura, Masatomo ^b   Uno, Tsukasa ^c   Yasui Furukori, Norio ^d   Hayakari, Makoto ^a   Tateishi, Tomonori ^d   Suzuki, Toshio ^b  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

Author keywords

AUC; Enantiomer; Lansoprazole; Limited sampling strategy

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 INHIBITOR; FLUVOXAMINE; LANSOPRAZOLE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; ENANTIOMER; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TECHNIQUE; TIME POINT SAMPLING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; GENOTYPE; HALF-LIFE; HUMANS; MALE; MODELS, BIOLOGICAL; PROTON PUMP INHIBITORS; STEREOISOMERISM;

EID: 41049102159     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0455-5     Document Type: Article

References (31)

1. Nagaya H, Satoh H, Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289-1295
2. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181-202
3. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361
4. Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG (2002) Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 72:90-99
5. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492
6. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T (2004) Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 60:623-628
7. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG (2003) Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31:1227-1234
8. Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M (2001) Role of CYP3A and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 57:709-715
9. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T (2005) Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol 60:61-68
10. Miura M (2006) Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 126:395-402
11. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T (2001) Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492
12. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T (2001) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 15:793-803
13. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561
14. Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L (2002) Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 71:141-152
15. Figgitt DP, McClellan KJ (2000) Fluvoxamine, an updated review of its use in the management of adults with anxiety disorders. Drugs 60:925-954
16. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T (2004) Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 44:1223-1229
17. Moore KH, Leese PT, McNeal S, Gray P, O'Quinn S, Bye C, Sale M (2002) The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin Ther 24:583-594
18. Ushiama H, Echizen H, Nachi S, Ohnishi A (2002) Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther 72:33-43
19. Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T (2005) Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 59:302-309
20. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T (2005) Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. Chirality 17:338-344
21. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
22. Miura M, Tada H, Suzuki T (2004) Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 804:389-395
23. Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T (2005) Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci 816:309-314
24. Niioka T, Yasui-Furukori N, Uno T, Sugawara K, Kaneko S, Tateishi T (2006) Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. Ther Drug Monit 28:321-325
25. Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37:399-431
26. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M (1993) Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45:367-371
27. Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI (1993) Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 36:391-398
28. Furuta T, Sugimoto M, Shirai N, Ishizaki T (2007) CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 8:1199-1210
29. Chong E, Ensom MH (2003) Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23:460-471
30. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH (2006) The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 101:1467-1475
31. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453-460